{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"12.5","value":"5.5"},{"comment":"The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.","groupId":"OG001","lowerLimit":"1.7","upperLimit":"NA","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set comprises of all participants who received at least one dose of study drug and have measurable disease as determined by the Investigator at baseline.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Duration of Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}